OpSec Blog

 Insights on Anti-Counterfeiting & Brand Protection Solutions

Avastin Scandal Throws a Spotlight on Trade-Activity Monitoring

Posted by admin on Feb 23, 2012 5:20:19 AM
In the ongoing counterfeit Avastin scandal, it has become clear that this was not a case of products so closely mimicking legitimate product that buyers were fooled. FDA, which published photos of the fake product, noted that it has the wrong manufacturer displayed, and has obviously bogus lot numbers. Rather, the fake product simply went via a non-standard distribution chain, from (apparently) a specialty distributor into clinics and doctors’ offices. (Some doctors, especially oncologists, purchase and dispense products directly rather than sending patients to a pharmacy, as do most hospitals; the completely legal practice is known as “buy and bill.”) If the doctors buying the fake product are not profoundly negligent, then they must be extremely naïve.

For the complete story, please visit Pharmaceutical Commerce.

Topics: Online Brand Protection, Pharmaceuticals